• 1
    Patnaik MM,Rindos M,Kouides PA, et al. Systemic mastocytosis: A concise clinical and laboratory review. Arch Pathol Lab Med 2007; 131: 784791.
  • 2
    Azana JM,Torrelo A,Mediero IG, et al. Urticaria pigmentosa: A review of 67 pediatric cases. Pediatr Dermatol 1994; 11: 102106.
  • 3
    Middelkamp Hup MA,Heide R,Tank B, et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol 2002; 16: 115120.
  • 4
    Travis WD,Li CY,Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore). 1988; 67: 345368.
  • 5
    Lawrence JB,Friedman BS,Travis WD, et al. Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91: 612624.
  • 6
    Lim K-H,Tefferi A,Lasho T, et al. Systemic mastocytosis in 342 consecutive adults. Blood 2009; 113: 57275736.
  • 7
    Longley BJ,Tyrrell L,Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312314.
  • 8
    Longley BJJr,Metcalfe DD,Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 16091614.
  • 9
    Garcia-Montero AC,Jara-Acevedo M,Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 23662372.
  • 10
    Lim KH,Pardanani A,Tefferi A. KIT and mastocytosis. Acta Haematol 2008; 119: 194198.
  • 11
    Tefferi A,Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 1422.
  • 12
    Valent P,Akin C,Escribano L, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435453.
  • 13
    Tefferi A,Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004; 11: 5864.
  • 14
    Casassus P,Caillat-Vigneron N,Martin A, et al. Treatment of adult systemic mastocytosis with interferon-α: Results of a multicentre phase II trial on 20 patients. Br J Haematol 2002; 119: 10901097.
  • 15
    Kluin-Nelemans HC,Jansen JH,Breukelman H, et al. Response to interferon α-2b in a patient with systemic mastocytosis. N Engl J Med 1992; 326: 619623.
  • 16
    Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998; 138: 489495.
  • 17
    Hauswirth AW,Simonitsch-Klupp I,Uffmann M, et al. Response to therapy with interferon α-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res 2004; 28: 249257.
  • 18
    Kluin-Nelemans HC,Oldhoff JM,Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 42704276.
  • 19
    Tefferi A,Li CY,Butterfield JH, et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344: 307309.
  • 20
    Pardanani A,Hoffbrand AV,Butterfield JH, et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127131.
  • 21
    Pardanani A,Elliott M,Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535536.
  • 22
    Droogendijk HJ,Kluin-Nelemans HJ,van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial. Cancer 2006; 107: 345351.
  • 23
    Vega-Ruiz A,Cortes JE,Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33: 14811484.
  • 24
    Valent P,Horny H-P,Li C-Y, et al. Mastocytosis (Mast Cell Disease). In: JaffeE, HarrisN, SteinH, VardimanJ, editors. WHO Classification of Tumours Pathology and Genetics Tumours of Haematopoetic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp 291302.
  • 25
    Vardiman JW,Brunning RD,Arber DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: SwerdlowSH CE, HarrisNL, JaffeES, PileriSA, SteinH, ThieleJ, VardimanJW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp 1830.
  • 26
    Tefferi A,Levine RL,Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900904.
  • 27
    Tefferi A,Pardanani A,Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905911.
  • 28
    Tefferi A,Lim KH,Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 13431345.
  • 29
    Pardanani A,Brockman SR,Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 30383045.
  • 30
    Pardanani A,Lasho TL,Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: Assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83: 457459.
  • 31
    Zermati Y,De Sepulveda P,Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003; 22: 660664.
  • 32
    Akin C,Fumo G,Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 32223225.
  • 33
    Akin C,Brockow K,D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686692.
  • 34
    Lortholary O,Vargaftig J,Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: A french multicenter study of 33 patients. ASH Annu Meeting Abstr 2004; 104: 661.
  • 35
    Penack O,Sotlar K,Noack F, et al. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. Ann Hematol 2005; 84: 692693.
  • 36
    Verstovsek S,Tefferi A,Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14: 39063915.
  • 37
    Gotlib J,George TI,Corless C, et al. The kit tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial. ASH Annu Meeting Abstr 2007; 110: 3536.